Oncologist. The. ASCO 2000: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. ABSTRACT
|
|
- Prudence Leonard
- 5 years ago
- Views:
Transcription
1 The Oncologist ASCO 2000: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA Key Words. Small cell lung cancer Non-small cell lung cancer Treatment Metastatic disease ABSTRACT Have we made any progress in the treatment of advanced non-small cell lung cancer (NSCLC) over the past 15 years? After hearing the Eastern Cooperative Oncology Group (ECOG) 1594 presented by Dr. Joan Schiller at the plenary session of the 36th Annual Meeting of ASCO, it is hard to be certain. Schiller reported the results of one of the world s largest randomized trials in metastatic lung cancer comparing four platinum-based doublets. There were no differences in survival (primary endpoint) or response between these four regimens, although the cisplatin/gemcitabine arm had a superior time to progression. In her commentary METASTATIC NON-SMALL CELL LUNG CANCER A Randomized Phase III Trial of Four Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (NSCLC). JH Schiller, D Harrington, A Sandler, C Belani, C Langer, J Krook, DH Johnson (ABSTRACT 2). Study Design and Results Eastern Cooperative Oncology Group (ECOG 1594) was a randomized trial of four chemotherapy regimens for patients with advanced NSCLC [1]. Eligible patients had either stage IV NSCLC or wet stage 3B (malignant pleural effusion). Patients were stratified by performance status, weight loss, stage and presence of brain metastases. The primary endpoint of this trial was survival, with response rate, time to progression and toxicity assessment on this study, Dr. Francis Shepherd concluded that progress in the treatment of metastatic lung cancer has occurred at a snail s pace. Despite the disappointing results of ECOG 1594, there were notable trials describing new agents with novel mechanisms of action reported at this year s ASCO meeting. In small-cell lung cancer, the combination of cisplatin/ irinotecan was found to be superior to cisplatin/etoposide. For NSCLC, novel agents Iressa anti-epidermal growth factor receptor tyrosine kinase and anti-vascular endothelial growth factor monoclonal antibody appear promising. The Oncologist 2000;5: being secondary endpoints. There were no formal cost comparisons or quality-of-life evaluations. From October 1996 until May 1999, 1,207 patients were randomized into one of the four following arms shown in Table 1. The characteristics of the 1,207 patients are shown in Table 2. Initially patients were eligible with performance status (PS) 0, 1, or 2. However, the poor outcome in the PS- 2 patients resulted in restricting the eligibility to those with PS-0, 1. The groups were well balanced for known prognostic factors. The number of patients who were ineligible was similar across all four arms. The efficacy results of this study are shown in Table 3. All tests for significance were comparisons between a study arm and the cisplatin/24-h paclitaxel control arm. There were no significant differences in terms of response, median survival or one-year survival. Cisplatin/gemcitabine (Arm B) Downloaded from by guest on October 14, 2018 Correspondence: Thomas J. Lynch, Jr., M.D., Massachusetts General Hospital Cancer Center, Hematology-Oncology Department, Room 201 Cox Building, 100 Blossom Street, Boston, Massachusetts , USA. Telephone: ; Fax: ; lynch.thomas@mbh.harvard.edu Received June 29, 2000; accepted for publication June 29, AlphaMed Press /2000/$5.00/0 The Oncologist 2000;5:
2 Lynch 275 Table 1. Design of ECOG 1594 Arm A Cisplatin 75 mg/m 2 day 2 Paclitaxel 135 mg/m 2 /24 h day 1 q 3 weeks Arm B Cisplatin 100 mg/m 2 day 1 Gemcitabine 1,000 mg/m 2 day 1, 8, 15 q 4 weeks Arm C Cisplatin 75 mg/m 2 day 1 Docetaxel 75 mg/m 2 day 1 q 3 weeks Arm D Carboplatin area under the concentration time curve 6 day 1 Paclitaxel 225 mg/m 2 /3 h day 1 q 3 weeks Table 2. Patient characteristics for ECOG 1594 A B C D Cis/Pac24 Cis/Gem Cis/Doc Carb/Pac3 n of patients 292% 288% 293% 290% Age 62% 64% 63% 62% Sex (% male) 64% 61% 62% 62% PS = 0, 1 94% 95% 94% 95% Brain mets 12% 14% 13% 12% Weight loss 34% 33% 32% 34% Table 3. Results of ECOG 1594 A B C D Cis/Pac24 Cis/Gem Cis/Doc Carb/Pac3 n of patients Response rate (%) 21.3% 21.0% 17.3% 15.3% Time to progression (mo.) ** Median survival (mo.) One-year survival (%) 31.0% 36.0% 31.0% 35.0% Table 4. Selected toxicities from ECOG 1594 A B C D Cis/Pac24 Cis/Gem Cis/Doc Carb/Pac3 n of patients Grade 3/4 F/N 2/14 1/3** 1/9 0/4** Grade 3/4/5 renal 3/0/0 5/3/1** 3/0/0 1/0/0 Grade 3 nausea ** Grade 3/4 vomiting 3/21 7/29 3/18 2/7** Grade 3/4 hypersensitivity 1/1 0/0 5/2** 1/1 Grade 3 neuropathy F/N=Fever/Neutropenia was superior in terms of time to progression compared to the control arm of cisplatin/paclitaxel 24-h. As expected there were significant differences in toxicity between the treatment arms. Overall there were significantly fewer grade 4 toxicities in the carboplatin/paclitaxel arm than in the cisplatin/paclitaxel arm. Significantly more patients stopped therapy because of progressive disease in the carboplatin/paclitaxel arm compared with cisplatin/ paclitaxel, and significantly more patients stopped for toxicity in the cisplatin/gemcitabine arm compared to cisplatin/ paclitaxel. Selected grade 3, 4, and 5 adverse events are shown in Table 4. Commentary ECOG 1594 was chosen as a plenary session presentation because it is an important trial that reflects the state of care in 2000 of metastatic NSCLC the leading cause of cancer-related death in North America. The results of this ECOG study are compared to the Southwest Oncology Group (SWOG) 9508 [2] reported at ASCO in 1999 in Table 5. The carboplatin/paclitaxel arms are identical in design between the two studies. These are important studies to compare because they were conducted at nearly the same time and in very similar (though not identical) patient populations. The median and one-year survival is similar for both carboplatin/paclitaxel arms. However, the response rate seen in the carboplatin/paclitaxel arm of ECOG 1594 is lower than that reported in the SWOG study from last year. This trend of the response rates being lower in ECOG 1594 is followed for both the gemcitabine and 24-h paclitaxel arms. The response rates for cisplatin/gemcitabine (21%) are lower than the (30%) response rate observed in Dr. Sandler s large North American trial reported in the Journal of Clinical Oncology this year [3] and shown in Table 6. Finally, as seen in Table 7, the cisplatin/paclitaxel response rate is lower than that reported in the prior ECOG study by Bonomi et al. (30%) [4]. There are several possible reasons for the lower response rates seen in all four Table 5. Comparison between ECOG 1594 and SWOG 9508 ECOG 1594 SWOG 9508 Carb/Pac3 Carb/Pac3 n of patients Response rate 15.3% 25% Median survival (mo.) One-year survival 35% 38% Grade 4 ANC 43% 36% Grade 3 nausea 8% 7%
3 276 Lung Cancer Highlights Table 6. Comparison between ECOG 1594 and Sandler study ECOG 1594 Sandler Cis/Gem Cis/Gem n of patients Response rate 21% 30.4% Median survival (mo.) One-year survival 36% 39% Grade 4 ANC 39% 35% Grade 3 nausea 37% 36% Table 7. Comparison between ECOG 1594 and ECOG 5592 ECOG 5592 ECOG 1594 Cis/Pac24 Cis/Pac24 n of patients Response rate 25.3% 21.3% Median survival (mo.) One-year survival 37.4% 31% Grade 4 ANC 74% 57% Grade 3 nausea 10% 25% arms of this study. First, the current study allowed patients with brain metastases to participate. Second, the stage IIIB patients on the ECOG study were those with malignant effusions rather than N3 adenopathy. Also, with the growing acceptance and momentum favoring treatment of patients with metastatic NSCLC, investigators are placing patients on trial that are more reflective of the general population of lung cancer patients. How important is response rate? Survival in the ECOG, SWOG, and Sandler trials is remarkably similar. While response rate is a useful surrogate marker, survival is ultimately the best indicator of the success or failure of a treatment. The median and one-year survivals have clearly improved over the past 20 years. While some of this is likely due to better drugs, much of the gain is from stage migration. As we aggressively scan patients for stage III treatment protocols, we are discovering a better class of stage IV patient to enter into stage IV trials and thus improve overall survival of this group. Overall survival will continue to be the most reliable measure of treatment efficacy in NSCLC trials. The current ECOG trial is the first to be done since the acceptance and growing use of second-line chemotherapy for NSCLC. The study by Shepherd et al. [5] clearly demonstrates that docetaxel is able to significantly prolong survival in previously treated patients. This raises the question of whether time to progression will ultimately become the most important measure in NSCLC trials rather than survival. One explanation for the failure to see a difference in overall survival between the four arms of the current ECOG trial is that second-line therapy obscured any benefits seen. Unfortunately data on second-line therapy were not gathered for this study. Clearly we have reached our limit in developing doublet platinum-based combinations for advanced NSCLC. It is highly unlikely that further trials of platinum doublets are going to produce results much different from those reported by ECOG. Triplet combinations will be pursued, as they should, but they too are unlikely to produce clinically meaningful advances for patients with lung cancer. The future of chemotherapy for NSCLC may rest with sequential use of single agents. The Cancer and Leukemia Group B (CALGB) is testing single-agent paclitaxel versus carboplatin/paclitaxel, and this study will be an important step in answering this question. The finding that second-line therapy of metastatic lung cancer benefits patients with NSCLC adds to the case for sequential single-agent therapy. Ultimately new drugs against new targets are the future of lung cancer therapy. Cooperative groups in the United States will now move forward and test novel agents and combinations of novel agents and established chemotherapy in future trials. A Randomized Phase II Trial Comparing Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor (rhumab VEGF) Plus Carboplatin/Paclitaxel (CP) to CP Alone in Patients with Stage IIIB/IV NSCLC. RF DeVore, L Fehrenbacher, RS Herbst, CJ Langer, K Kelly, J Gaudreault, E Holmgren, WF Novotny, F Kabbinavar (ABSTRACT 1896). Study Design and Results A consortium of centers led by Dr. Russell DeVore conducted a randomized phase II trial of carboplatin/paclitaxel with recombinant humanized monoclonal anti-vegf antibody [6]. All patients had stage IIIB (pleural effusion), stage IV or recurrent disease. Patients were eligible only if they had received no prior chemotherapy. The primary endpoints were time to progression, response rate and safety. Overall survival was a secondary endpoint. Ninety-nine patients were randomized to either carboplatin (AUC6)/paclitaxel 200 mg/m 2 (Arm 1), same chemo mg/kg anti-vegf (Arm 2) or same chemo + 15 mg/kg anti-vegf (arm 3). Time to progression was chosen as an endpoint because this was a randomized phase II study and patients on the chemoalone arm were allowed to cross over to anti-vegf upon progression. Patient characteristics were reflective of the standard population of patients in advanced lung cancer trials. There was an imbalance by sex with more men being in the CP-alone arm.
4 Lynch 277 When responses were analyzed, the response rate to CP with 15 mg/kg of anti-vegf was 40%. Furthermore, when patients with large masses that had become cavitated (but did not change their overall size) were factored in, the response rate was 51% in this arm. There was also a trend (not statistically significant) favoring time to progression in the chemotherapy + 15 mg/kg arm. Toxicity was a major concern in this trial. Six patients treated with chemotherapy plus antibody had life-threatening hemoptysis and four died. The deaths were all in patients with squamous cell cancer. The remainder of toxicity was well balanced between all three groups, with the exception of more diarrhea in the antibody arms. Commentary This study is one of the first to randomly compare a novel agent with chemotherapy versus chemotherapy alone. VEGF is an intriguing target for lung cancer since it is overexpressed in pulmonary neoplasms and has been associated with a poor prognosis. The trial by DeVore et al. demonstrated that the anti-vegf antibody has both potentially exciting activity and potentially devastating toxicity. The median survival of the chemo + 15 mg/kg anti-vegf arm of 17 months is among the highest ever reported for advanced lung cancer. This undoubtedly is due in a large part to patient selection. However, the impressive response rate and the unusual cavitation seen in these lesions is supportive of this drug having activity. The major question is whether toxicity will prohibit further development of this agent. Are there ways to predict who will develop toxicity? Would prophylactic irradiation to the mediastinum prevent fatal hemoptysis? The next step in the development of this agent will be a randomized ECOG phase III study comparing CP alone to CP with 15 mg/kg of anti-vegf. The principle endpoint of the ECOG study will be overall survival, and there will be no cross over between the two arms of the study. In one respect the occurrence of hemoptysis actually supports the activity of this agent from a mechanistic standpoint. SMALL CELL LUNG CANCER Randomized Phase III Study of Irinotecan (CPT-11) and Cisplatin Versus Etoposide and Cisplatin in Extensive- Disease Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG9511). K Noda, Y Nishiwaki, M Kawahara, S Negoro, T Sugiura, A Yokoyama, M Fukuoka, K Mori, K Watanabe, T Tamura, N Saijo, K Yoshimura (ABSTRACT 1887). Study Design and Results The study by Noda et al. [7] was a randomized phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin. Etoposide and cisplatin were chosen as the reference arm in this trial. Eligible patients included patients with extensive stage small-cell lung cancer (SCLC) with a good PS. Overall survival was the primary endpoint of this study. One hundred fifty-four patients were randomized between two arms. The control arm was cisplatin 80 mg/m 2 /day 1 with VP-16 (etoposide) 100 mg/m 2 /day 1, 2, 3 given every three weeks for four courses. The study arm was cisplatin 60 mg/m 2 /day 1 with CPT-11 (irinotecan) 60 mg/m 2 /day 1, 8, 15 every four weeks for four cycles. The use of G-CSF was allowed for recovery of counts. The original sample size was significantly larger, but the trial was stopped early when the interim analysis showed a significant benefit to the experimental arm in terms of improved overall survival. Patient characteristics and outcome data are shown in Table 8. Nonhematologic toxicities were generally similar between the two groups with the exception of more diarrhea in the irinotecan arm. There were three deaths on study on the irinotecan arm and one death on the etoposide arm. This rate of toxicity is similar to that seen in other trials in extensive SCLC. Study Design and Results 1886 Topotecan (T) versus Observation (OB) Following Cisplatin (P) Plus Etoposide (E) in Extensive Stage Small Cell Lung Cancer (ES SCLC) (E7593): A Phase III Trial of the Eastern Cooperative Oncology Group (ECOG). DH Johnson, S Adak, DF Cella, RF DeVore, A Marcus, JH Schiller (ABSTRACT 1886). ECOG presented a randomized trial of four cycles of topotecan following standard doses of cisplatin/etoposide in extensive stage SCLC [8]. Eligible patients had measurable disease with a good PS. Patients were allowed to have clinically stable central nervous system metastases. All Table 8. Results of randomized trial of cisplatin/etoposide versus cisplatin/irinotecan in extensive SCLC CPT-11/Cisplatin VP-16/Cisplatin n of patients Median age PS 0, 1 (%) 92% 87% Weight loss <5% 71% 73% Grade 4 neutropenia 25.7% 64.9% Grade 4 thrombocytopenia 4% 0% Overall response rate 83.1% 67.5% Median survival 12.8** 9.4 One-year survival 58.4%** 37.7% Two-year survival 18.9%** 6.5%
5 278 Lung Cancer Highlights Table 9. Results of ECOG 7593 Observation Topotecan n of patients Disease-free survival 2.3 months 3.6 months** Median survival 8.9 months 9.3 months** One-year survival 27% 25% patients received four cycles of cisplatin 60 mg/m 2 /day 1 and etoposide 120 mg/m 2 /day 1, 2, 3. Patients who progressed were taken off the study. All others were randomized to either observation or topotecan 1.5 mg/m 2 /day 5 days, q three weeks for four cycles. ECOG registered 405 patients into the initial therapy with etoposide and cisplatin. Two hundred twenty-seven patients were randomized to either observation or topotecan. Patient characteristics and study results are shown in Table 9. The median survival of all 405 patients was 9.6 months with 35% of patients living one year. The complete and partial response rate was 33% to the induction therapy. The observation arm was not associated with any grade 4 hematologic toxicity, while the topotecan arm had 60% grade 4 neutropenia and 13% grade 4 thrombocytopenia. Nonhematologic toxicity was unusual. Commentary on Abstracts 1886 and 1887 For patients with extensive stage SCLC, there has been little progress over the past 20 years since the establishment of etoposide and cisplatin as the standard of care. At this year s ASCO meeting, two studies tried to improve upon the results found with etoposide and cisplatin. In the ECOG study, four cycles of topotecan added toxicity but did not REFERENCES 1 Schiller J, Harrington D, Sandler A et al. A Randomized Phase III Trial of Four Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (NSCLC). [Abstract 2] 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, Kelly K, Crowley J, Bunn P et al. A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in Untreated Advanced NSCLC: A Southwest Oncology Group Trial. [Abstract 1777] 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, Sandler A, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18: Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung enhance overall survival. Disease-free survival was prolonged by 1.3 months (five weeks). It is not likely that a five-week prolongation of disease-free survival is significant enough to change the standard of practice, particularly when there was no change in overall survival and toxicity was present. Topotecan is one of most active new agents for SCLC. It is particularly disappointing that it has been so hard to bring this agent to front-line therapy. In the poster session on Tuesday, the CALGB reported [9] a trial in extensive SCLC that combined topotecan with paclitaxel and achieved a 9.4- month median survival, similar to the ECOG data with cisplatin/etoposide. Dr. James Jett from the Mayo Clinic [10] presented data with etoposide/cisplatin alternating with topotecan/paclitaxel and found a median survival of 10.5 months. In none of these trials has topotecan produced an overall survival rate superior to that seen with etoposide/cisplatin alone. An alternative may be found in the use of irinotecan. Like topotecan, irinotecan is a topoisomerase I inhibitor with good activity in patients with lung cancer. The JCOG data show a prolongation of survival using irinotecan compared to etoposide when combined with cisplatin. The Japanese study showed an impressive survival advantage to the newer combination. If this is confirmed, this may become the new standard of care for SCLC. The toxicity associated with this regimen was acceptable. In both of these trials, the number of cycles of etoposide/cisplatin used in the control arm was four. For many this will represent a departure from the previous standard of six cycles. The data with four cycles in these two most recently completed studies are remarkably similar to data using six cycles of therapy, leading Dr. David Johnson from ECOG to conclude that four cycles should be the standard duration of therapy for extensive stage SCLC. This is a very reasonable recommendation. cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18: Shepherd F, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18: DeVore R, Fehrenbacher L, Herbst R et al. A Randomized Phase II Trial Comparing Rhumab VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) Plus Carboplatin/Paclitaxel (CP) to CP Alone in Patients with Stage IIIB/IV NSCLC. [Abstract 1896] 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 2000.
6 Lynch Noda K, Nishiwaki Y, Kawahara M et al. Randomized Phase III Study of Irinotecan (CPT-11) and Cisplatin Versus Etoposide and Cisplatin in Extensive-Disease Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG9511). [Abstract 1887] 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, Johnson D, Adak S, Cella D et al. Topotecan (T) vs. Observation (OB) Following Cisplatin (P) Plus Etoposide (E) in Extensive Stage Small Cell Lung Cancer (ES SCLC) (E7593): a Phase III Trial of the Eastern Cooperative Oncology Group (ECOG). [Abstract 1886] 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, Lynch T, Herndon J, Lyss A et al. Paclitaxel (P) + Topotecan (T) + GCSF for Previously Untreated Extensive Small Cell Lung Cancer (E-SCLC): Preliminary Analysis of Cancer and Leukemia Group B (CALGB) [Abstract 1922] 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, Jett J, Hatfield A, Bauman M et al. Phase II Trial of Topotecan and Paclitaxel (TP) with G-CSF Support Alternating with Etoposide and Cisplatin (EC) in Previously Untreated Extensive Stage Small Cell Lung Cancer (ED-SCLC). [Abstract 1921] 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 2000.
7 Errata BURNOUT: CARING FOR THE CAREGIVERS Richard T. Penson, Fiona L. Dignan, George P. Canellos, Carol L. Picard, Thomas J. Lynch, Jr. The Oncologist 2000;5: In the Acknowledgment section on page 434, Lisa Kreuderberger should read Lisa Freuderberger. LUNG CANCER HIGHLIGHTS Thomas J. Lynch, Jr. The Oncologist 2000;5: In Tables 3 and 6, the median survival time in the Gem/Cis arm of the study should be 8.1 months rather than 8.8 months.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
The Oncologist Mayo Clinic Hematology/Oncology Reviews Is There a Preferred Combination Chemotherapy Regimen for Metastastic Non-Small Cell Lung Cancer? DAVID S. ETTINGER Sidney Kimmel Comprehensive Cancer
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationKey Words. Bevacizumab Avastin Nonsquamous Non-small cell lung cancer First-line Advanced/metastatic disease
The Oncologist Regulatory Issues: FDA FDA Drug Approval Summary: Bevacizumab (Avastin ) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell
More informationOncologist. The. ASCO 1999: Critical Commentaries. Lung Cancer Highlights THOMAS J. LYNCH, JR. The Oncologist 1999;4:
The Oncologist ASCO 1999: Critical Commentaries Lung Cancer Highlights THOMAS J. LYNCH, JR. Massachusetts General Hospital, Boston, Massachusetts, USA Adjuvant therapy does not work. Second-line therapy
More informationAuthor(s) Ohmatsu, Hironobu; Kubota, Kaoru; N. Citation Respiratory medicine (2010), 104(3)
Title Trends in chemotherapy for elderly non-small-cell lung cancer. Author(s) Kim, Young Hak; Yoh, Kiyotaka; Niho Ohmatsu, Hironobu; Kubota, Kaoru; N Citation Respiratory medicine (2010), 104(3) Issue
More informationSystemic chemotherapy improves both survival and quality
ORIGINAL ARTICLE Treatment of Elderly Non small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial Suresh Ramalingam,
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationLung cancer is the leading cause of cancer mortality in both
ORIGINAL ARTICLE Chemotherapy in Patients 80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and Paul J. Hesketh, MD,* Rogerio C. Lilenbaum, MD, Kari Chansky, MS, Afshin Dowlati,
More informationSmall cell lung cancer (SCLC) accounts for approximately
ORIGINAL ARTICLE A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer Jingwei
More informationThe New England Journal of Medicine COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON SMALL-CELL LUNG CANCER
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON SMALL-CELL LUNG CANCER JOAN H. SCHILLER, M.D., DAVID HARRINGTON, PH.D., CHANDRA P. BELANI, M.D., COREY LANGER, M.D., ALAN SANDLER, M.D., JAMES
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationChemotherapy in Lung Cancer
Special Issue Chemotherapy in Lung Cancer Keunchil Park, M.D. Division of Hematology / Oncology, Department of Medicine Sungkyunkwan University School of Medicine, Samsung Medical Center E-mail : kpark@smc.samsung.co.kr
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationLung cancer remains the leading cause of cancer-related
ORIGINAL ARTICLE Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer Cancer and Leukemia Group B Study 39901 Stephen L. Graziano, MD,* James E. Herndon, II, PhD, Mark
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationOncologist. The. Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review JAMES R. RIGAS LEARNING OBJECTIVES ABSTRACT
The Oncologist Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review JAMES R. RIGAS Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, USA Key Words.
More informationSCIENTIFIC DISCUSSION
London, 20 April 2005 Product name: PAXENE Procedure No. EMEA/H/C/399/II/26 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel:(44-20) 74 18 84, fax (44-20) 74 18 86 68 E-mail:
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationBelotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer
J Lung Cancer 2010;9(1):15-19 Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer Purpose: Belotecan (Camtobell R ; Chong Keun Dang Co., Seoul,
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationSystemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Suresh Ramalingam, a Chandra Belani b a Lung & Thoracic Malignancies Program, University of Pittsburgh
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationAHFS Final. line. Criteria Used in. combined. cisplatin. Strength. established was. Non-small Cell Lung. Cancer: of carboplatin and
Drug/Drug Combination: Cetuximab Off-label Use: First-line treatment of advanced non-small Use for Review: cell lung cancer Criteria Used in Selection of Off-labell AHFS Final Determination of Medical
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationSmall Cell Lung Cancer What we have now?
Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationCitation Cancer Management and Research, 2(1
NAOSITE: Nagasaki University's Ac Title Author(s) Efficacy and safety of amrubicin hy small cell lung cancer Ogawara, Daiki; Fukuda, Minoru; Nak Citation Cancer Management and Research, 2(1 Issue Date
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More informationThe treatment of advanced non-small cell lung cancer
ORIGINAL ARTICLE A Randomized Phase II Trial of Two Schedules of in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer Rogerio Lilenbaum, MD,* Mark Rubin, MD, Joyce Samuel,
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationAdvances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationPlatinum-based doublets are considered to be the standard
Blackwell Publishing Asia Review Article Recent trends in the treatment of advanced lung cancer Nagahiro Saijo 1 National Cancer Center, Hospital East, Kashiwanoha 6-5-1, Kashiwa-shi, Chiba 277-8577, Japan
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationFirst line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger
More informationONCOLOGY LETTERS 5: , 2013
ONCOLOGY LETTERS 5: 761-767, 2013 Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer TOSHIKI
More informationOncologist. The. Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer
The Oncologist Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer B.T. HENNESSY, a E.O. HANRAHAN, b O.S. BREATHNACH a,c a Department of Medical Oncology, Cork University
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationOptimizing First-Line Treatment Options for Patients with Advanced NSCLC
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Optimizing First-Line Treatment Options for Patients with Advanced
More informationLung cancer is the leading cause of cancer death in the
ORIGINAL ARTICLE A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly Yuh-Min Chen, MD, PhD,* Reury-Perng Perng,
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationIt is estimated that 215,020 cases of lung cancer were newly
ORIGINAL ARTICLE Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer Alan Sandler, MD,* Jing
More informationSCIENTIFIC DISCUSSION. London, 21 August 2007 Product Name: Avastin EMEA/H/C/582/II/09
SCIENTIFIC DISCUSSION London, 21 August 2007 Product Name: Avastin EMEA/H/C/582/II/09 Extension of the indication for first-line treatment of patients with unresectable advanced, metastatic or recurrent
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationBevacizumab treatment for advanced non small cell lung cancer: A case report
ONCOLOGY LETTERS 6: 1779-1783, 2013 Bevacizumab treatment for advanced non small cell lung cancer: A case report YUN FAN *, ZHIYU HUANG and WEIMIN MAO * Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationCâncer de Pulmão Não Pequenas Células
Câncer de Pulmão Não Pequenas Células Carboplatina + Paclitaxel Paclitaxel: 200mg/m 2 IV D1 Carboplatina: AUC 6 IV D1 a cada 21 dias X 4 ciclos Ref. (1) Vinorelbina + Cisplatina Vinorelbina: 25mg/m 2 IV
More informationLung cancer is the most common cause of cancer-related
GUIDELINES Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline Susanna Cheng, MD,* William K. Evans, MD, Denise Stys-Norman, PgDip, Frances A. Shepherd, MD, and
More informationYuh-Min Chen, MD, PhD; Reury-Perng Perng, MD, PhD; Jen-Fu Shih, MD; Chun-Ming Tsai, MD; and Jacqueline Whang-Peng, MD
Chemotherapy for Non-small Cell Lung Cancer in Elderly * Yuh-Min Chen, MD, PhD; Reury-Perng Perng, MD, PhD; Jen-Fu Shih, MD; Chun-Ming Tsai, MD; and Jacqueline Whang-Peng, MD Study objective: To determine
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationSmall cell lung cancer (SCLC) accounts for 13 to 15% of
ORIGINAL ARTICLE Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationChemotherapy with etoposide and cisplatin or carboplatin
Brief Report A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationdoi: /theoncologist originally published online February 3, 2009
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line? Cesare Gridelli, Paolo Maione, Antonio Rossi, Marianna Luciana Ferrara, Maria Anna
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationOriginal article. Introduction. survival times (MSTs) from 8 to 11 months in this patient population
Original article Annals of Oncology 14: 709 714, 2003 DOI: 10.1093/annonc/mdg213 Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive
More informationLocally advanced unresectable non small cell lung cancer
ORIGINAL ARTICLE Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer Ikuo Sekine,*
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationThe treatment outcome in patients with advanced nonsmall
ORIGINAL ARTICLE Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III Trials Katsuyuki Hotta,
More informationPhase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
Original article Annals of Oncology 13: 1862 1867, 2002 DOI: 10.1093/annonc/mdf308 Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer V.
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationLarge-cell neuroendocrine carcinoma (LCNEC) and
BRIEF REPORT Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung A Multicenter Phase II Study Seiji Niho, MD, PhD,* Hirotsugu Kenmotsu, MD, Ikuo Sekine,
More informationA Phase II Study of Amrubicin and Topotecan Combination Therapy in Patients. with Relapsed or Extensive-Disease Small-Cell Lung Cancer: Okayama Lung
1 2 3 A Phase II Study of Amrubicin and Topotecan Combination Therapy in Patients with Relapsed or Extensive-Disease Small-Cell Lung Cancer: Okayama Lung Cancer Study Group Trial 0401 4 5 6 7 8 9 Naoyuki
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationThe Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(4):638-644 Original Article http://dx.doi.org/10.4143/crt.2014.316 Open Access The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationSystemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and the Lung Cancer Disease Site Group
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and
More informationLUNG. Tumour Group: Regimen name / acronym. Place in therapy. Induction chemotherapy. Regimen name / acronym. Place in therapy
Tumour Group: LUNG Non-small cell lung cancer Adjuvant Vinorelbine PO* / Cisplatin 1 x x First line Vinorelbine IV / Cisplatin x First line Vinorelbine IV / Carboplatin x cisplatin Vinorelbine PO* / Cisplatin
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationGenitourinary Cancer. The Role of Taxanes in the Management of Bladder Cancer. The Oncologist 2005;10: Matthew D.
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Genitourinary Cancer The Role of Taxanes in the Management of
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More information